HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Stefano Margaritora Alfredo Cesario Domenico Galetta Pierluigi Granone Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Margaritora, S. Articles by Granone, P. Search for Related Content PubMed PubMed Citation Articles by Margaritora, S. Articles by Granone, P. Related Collections Lung - cancer

Eur J Cardiothorac Surg 2001;19:894-898
© 2001 Elsevier Science NL

Ten year experience with induction therapy in locally advanced non-small cell lung cancer (NSCLC): is clinical re-staging predictive of pathological staging?

^a General Thoracic Surgery, Department of General Surgery, Catholic University, Rome, Italy
^b Department of Radiology, Catholic University, Rome, Italy
^c Department of Radiotherapy, Catholic University, Rome, Italy

Received 7 October 2000; received in revised form 20 March 2001; accepted 21 March 2001.

Corresponding author. Tel.: +39-0335-8366161; fax: +39-06-3051162
e-mail: alfcesario{at}yahoo.com

Objective: To verify if in our experience with ‘induction therapy’ in non-small cell lung cancer (NSCLC) the clinical re-staging is really predictive of pathological staging. Materials and methods: From January 1990 to February 2000, 136 patients with locally advanced NSCLC underwent a protocol of induction therapy according to three different treatment plans: Carboplatin+radiotherapy – study A; Cisplatin+5-Fluorouracil+radiotherapy – study B; Gemcitabine+radiotherapy – study C. Results: Clinical re-staging showed in the patients enrolled in study A a clinical Complete Response rate (cCR) of 2.3%; a clinical Partial Response rate (cPR) of 50%; a clinical Stable Disease (cSD) rate of 44.3%; a clinical Disease Progression (cDP) rate of 3.4%. In study B, cCR was 0%; cPR: 71.4%; cSD 10.7%; cDP: 17.9%. In study C, cCR was 0%; cPR: 23.5%; cSD: 11.8%; cDP: 64.7%. After clinical re-staging, 76 patients (47 group A; 23 group B; 6 group C) were judged to be resectable and underwent a surgical operation. Pathological staging showed no tumour in eight patients (10.5%; 8/76) (three in study A, four in study B, one in study C) and microscopic neoplastic remnants in seven (9.2%; 7/76). Thirty-nine patients were pN0. Overall downstaging rate in the operated patients was 51%. No precise correlation was found among clinical re-staging and pathological staging. We had two cCRs and eight pCRs, and all of these pCRs had been re-staged as cPR except in one case (cSD). In seven cases, where only microscopic remnants have been found, six had been clinically restaged as cPR and one as cSD. Conclusions: Our experience confirmed how often the clinical re-staging data are unreal. Accordingly surgery should be indicated in any case where an induction therapy has been administered, if it is reasonably possible.

Key Words: Non-small cell lung cancer • Induction therapy • Clinical staging • Clinical restaging • Pathological staging

This article has been cited by other articles:

				L. A. Robinson, J. C. Ruckdeschel, H. Wagner Jr, and C. W. Stevens Treatment of Non-small Cell Lung Cancer-Stage IIIA: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 243S - 265S. [Abstract] [Full Text] [PDF]

				M. Serra, L. Occhionero, and D. Galetta Complete Response Following Preoperative Chemotherapy for Resectable Non-small Cell Lung Cancer. Chest, October 1, 2006; 130(4): 1284 - 1285. [Full Text] [PDF]

				B. Milleron, V. Westeel, E. Quoix, D. Moro-Sibilot, D. Braun, B. Lebeau, A. Depierre, and for the French Thoracic Cooperative Group Complete Response Following Preoperative Chemotherapy for Resectable Non-Small Cell Lung Cancer: Accuracy of Clinical Assessment Using the French Trial Database Chest, September 1, 2005; 128(3): 1442 - 1447. [Abstract] [Full Text] [PDF]

				A. Cesario, S. Margaritora, D. Galetta, V. Porziella, P. Granone, R. M. D'Angelillo, L. Trodella, V. Cardaci, S. Sterzi, and P. Russo Correspondence re L. J. Wirth et al., Induction Docetaxel and Carboplatin Followed by Weekly Docetaxel and Carboplatin with Concurrent Radiotherapy, Then Surgery in Stage III Non-Small Cell Lung Cancer: a Phase I Study. Clin Cancer Res 2003;9:1698-704. Clin. Cancer Res., April 15, 2004; 10(8): 2902 - 2903. [Full Text] [PDF]